Jim Simons
BBIO icon

Jim Simons’s BridgeBio Pharma BBIO Stock Holding History

Jim Simons’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8M Buy
856,846
+491,074
+134% +$34.4M 0.09% 257
2026
Q1 		$27.2M Buy
+365,772
New +$26.5M 0.04% 538
2025
Q4 		– Sell
-322,246
Closed -$16.7M – 3246
2025
Q3 		$16.7M Buy
322,246
+76,300
+31% +$3.72M 0.02% 819
2025
Q2 		$10.6M Buy
+245,946
New +$8.95M 0.01% 1028
2023
Q4 		– Sell
-584,146
Closed -$15.4M – 3736
2023
Q3 		$15.4M Buy
+584,146
New +$16.6M 0.03% 689
2023
Q2 		– Sell
-763,746
Closed -$12.7M – 3910
2023
Q1 		$12.7M Sell
763,746
-266,200
-26% -$3.1M 0.02% 965
2022
Q4 		$7.85M Sell
1,029,946
-336,800
-25% -$3.22M 0.01% 1237
2022
Q3 		$13.6M Buy
1,366,746
+953,500
+231% +$9.9M 0.02% 869
2022
Q2 		$3.75M Buy
+413,246
New +$3.46M ﹤0.01% 1765
2021
Q2 		– Sell
-118,546
Closed -$7.3M – 3452
2021
Q1 		$7.3M Buy
+118,546
New +$7.76M 0.01% 1400

Other funds holding BBIO

Jupiter Topco
Jupiter Topco New York $245B AUM
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Jim Simons's BBIO Position: Q2 2026 in Review

Jim Simons increased its BridgeBio Pharma (BBIO) stake by 134% in Q2 2026, buying an estimated $34.4M and bringing the position to 856,846 shares worth $63.8M. The position accounts for 0.09% of the portfolio, ranked #257.

Jim Simons first reported a position in BBIO in Q1 2021 and has held it in 10 quarters since. 476 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Jim Simons held 856,846 shares of BridgeBio Pharma worth $63.8M as of Q2 2026.
  • Jim Simons bought 491,074 BridgeBio Pharma shares in Q2 2026, an estimated $34.4M.
  • BridgeBio Pharma made up 0.09% of Jim Simons's portfolio in Q2 2026, its #257 holding.
  • Jim Simons first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 10 quarters since.
  • 476 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.